Novo Nordisk
272.25 DKK
+6.53 %
1,024 following
NOVO B
NASDAQ Copenhagen
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Quarter data
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Novo Nordisk
| Q3/24 | Q4/24 | 2024 | Q1/25 | Q2/25 | Q3/25 | Q4/25 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 71,311.0 | 85,683.0 | 290,403.0 | 78,087.0 | 76,857.0 | 74,976.0 | 79,144.0 | 309,064.0 |
| EBITDA | 35,972.0 | 41,935.0 | 147,446.0 | 42,621.0 | 38,282.0 | 31,439.0 | 37,298.0 | 149,640.0 |
| EBIT | 33,822.0 | 36,737.0 | 128,339.0 | 38,791.0 | 33,449.0 | 23,682.0 | 31,736.0 | 127,658.0 |
| EBIT-% | 47.4 % | 42.9 % | 44.2 % | 49.7 % | 43.5 % | 31.6 % | 40.1 % | 41.3 % |
| Profit before taxes | 34,384.0 | 35,557.0 | 127,191.0 | 37,033.0 | 33,805.0 | 25,517.0 | 34,185.0 | 130,540.0 |
| Net income | 27,301.0 | 28,230.0 | 100,988.0 | 29,034.0 | 26,503.0 | 20,006.0 | 26,891.0 | 102,434.0 |